ID   SK-MEL-93 DX-6
AC   CVCL_A434
AS   CVCL_U906
SY   SK-MEL-93-DX-6; SK-MEL-93 DX 6; SK-MEL-93 DX6; SK-MEL-93 (DX6); DX-6; DX6; SK-MEL-93(6); DX-Mel-6
DR   Cosmic; 721820
DR   Cosmic; 926005
DR   Cosmic; 933124
DR   Wikidata; Q54954346
RX   PubMed=1716514;
RX   PubMed=2886213;
RX   PubMed=2983346;
RX   PubMed=6976407;
RX   PubMed=9598804;
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=9598804).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Gly35Glu (c.104G>A); ClinVar=VCV000188292; Zygosity=Unspecified (PubMed=9598804).
CC   Derived from site: Metastatic; Hypodermis; UBERON=UBERON_0002072.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_5651 ! SK-MEL-93 DX-1
OI   CVCL_5652 ! SK-MEL-93 DX-2
OI   CVCL_5650 ! SK-MEL-93 DX-3
OI   CVCL_A432 ! SK-MEL-93 DX-4
OI   CVCL_A433 ! SK-MEL-93 DX-5
OI   CVCL_A435 ! SK-MEL-93 DX-B
SX   Female
AG   71Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 30-01-24; Version: 13
//
RX   PubMed=1716514;
RA   Albino A.P., Davis B.M., Nanus D.M.;
RT   "Induction of growth factor RNA expression in human malignant
RT   melanoma: markers of transformation.";
RL   Cancer Res. 51:4815-4820(1991).
//
RX   PubMed=2886213;
RA   Dracopoli N.C., Alhadeff B., Houghton A.N., Old L.J.;
RT   "Loss of heterozygosity at autosomal and X-linked loci during tumor
RT   progression in a patient with melanoma.";
RL   Cancer Res. 47:3995-4000(1987).
//
RX   PubMed=2983346; DOI=10.1073/pnas.82.5.1470;
RA   Dracopoli N.C., Houghton A.N., Old L.J.;
RT   "Loss of polymorphic restriction fragments in malignant melanoma:
RT   implications for tumor heterogeneity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:1470-1474(1985).
//
RX   PubMed=6976407; DOI=10.1084/jem.154.6.1764;
RA   Albino A.P., Lloyd K.O., Houghton A.N., Oettgen H.F., Old L.J.;
RT   "Heterogeneity in surface antigen and glycoprotein expression of cell
RT   lines derived from different melanoma metastases of the same patient.
RT   Implications for the study of tumor antigens.";
RL   J. Exp. Med. 154:1764-1778(1981).
//
RX   PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N;
RA   Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C.,
RA   Fountain J.W.;
RT   "Virtually 100% of melanoma cell lines harbor alterations at the DNA
RT   level within CDKN2A, CDKN2B, or one of their downstream targets.";
RL   Genes Chromosomes Cancer 22:157-163(1998).
//